IFRX
InflaRx N.V.
$1.66
-2.92%
$123.6M
No data for this timeframe.
Vol
Market Cap$123.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (79%)
SEC Reports6
Press Releases6
Recent Activity
Jun 5, 2026
short_volume
Short Volume: IFRX — 55.7% short (0.3M / 0.5M)
Short: 293,591 | Exempt: 18,221 | TRF Vol: 526,740 | Short Ratio: 55.7% | Off-exchange volume (dark
May 6, 2026
SEC
InflaRx filed a preliminary prospectus supplement for an underwritten offering of ordinary shares. The size and pricing
424B5 — Impact 5/10
May 6, 2026
SEC
InflaRx announced it will develop izicopan, an oral C5aR inhibitor, in ANCA-associated vasculitis (AAV) and additional r
6-K — Impact 7/10
May 6, 2026
Press
InflaRx announced a strategic pivot to develop izicopan in ANCA-associated vasculitis (AAV) and other renal diseases, wi
Impact 5/10
May 6, 2026
SEC
InflaRx reported Q1 2026 results: no revenue (GOHIBIC sales discontinued Dec 2025), net loss of €5.6M (improved from €8.
6-K — Impact 4/10
Apr 9, 2026
Press
InflaRx announced new in vitro data showing izicopan does not exhibit time-dependent inhibition of CYP3A4, a key enzyme
Impact 7/10
Price Targets
$7.87
+373.9% upside
Strong Buy
Current $1.66
Low $2.95
Median $8.83
High $13.73
7 analysts
$2.95
$13.73
Analyst Ratings
5Strong Buy
6Buy
3Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Raymond James | UPGRADE | Outperform → Strong Buy |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| May 11, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight → Overweight |
| Apr 21, 2026 | Guggenheim | REITERATE | Buy → Buy |
| Mar 20, 2026 | Guggenheim | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.06 ▲ +55.1% | $-0.07 — $-0.04 | 74% YoY | 4 |
| Next Q | $-0.05 ▲ +56.3% | $-0.07 — $-0.04 | 71% YoY | 4 |
| Current FY | $-0.30 ▲ +53.6% | $-0.56 — $-0.18 | 56% YoY | 5 |
| Next FY | $-0.37 ▲ +41.9% | $-0.78 — $-0.13 | -25% YoY | 5 |
Latest Reports
BEARISH
424B5
5/10
InflaRx filed a preliminary prospectus supplement for an underwritten offering of ordinary shares. The size and pricing
May 6, 2026
BULLISH
6-K
7/10
InflaRx announced it will develop izicopan, an oral C5aR inhibitor, in ANCA-associated vasculitis (AAV) and additional r
May 6, 2026
NEUTRAL
Press
5/10
InflaRx announced a strategic pivot to develop izicopan in ANCA-associated vasculitis (AAV) and other renal diseases, wi
May 6, 2026
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
6 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 4.3/10.
BEARISH
424B5
5/10
InflaRx filed a preliminary prospectus supplement for an underwritten offering of ordinary shares. T
May 6, 2026
BULLISH
6-K
7/10
InflaRx announced it will develop izicopan, an oral C5aR inhibitor, in ANCA-associated vasculitis (A
May 6, 2026
NEUTRAL
6-K
4/10
InflaRx reported Q1 2026 results: no revenue (GOHIBIC sales discontinued Dec 2025), net loss of €5.6
May 6, 2026
NEUTRAL
6-K
3/10
InflaRx announced preclinical data for izicopan showing lower reactive metabolite formation compared
May 4, 2026
NEUTRAL
PRESS-RELEASE
2/10
InflaRx announced it will publish Q1 2026 financial results on May 7, 2026, before market open. No f
May 1, 2026
NEUTRAL
6-K
5/10
InflaRx N.V. held its 2026 Annual General Meeting, approving routine corporate matters including the
Apr 23, 2026
NEUTRAL
5/10
InflaRx announced a strategic pivot to develop izicopan in ANCA-associated vasculitis (AAV) and othe
May 6, 2026
BULLISH
7/10
InflaRx announced new in vitro data showing izicopan does not exhibit time-dependent inhibition of C
Apr 9, 2026
BULLISH
7/10
InflaRx reported financial results for 2025, highlighted by a narrow improvement in net loss to €45.
Mar 19, 2026
BULLISH
8/10
InflaRx N.V. announced that Phase 3 data for its drug vilobelimab in pyoderma gangrenosum (PG) will
Mar 18, 2026
BEARISH
6/10
InflaRx N.V. received a Nasdaq delisting notice due to its share price closing below $1.00 for 30 co
Mar 13, 2026
NEUTRAL
3/10
InflaRx N.V. announced it will release its Q4 and full-year 2025 financial and operating results on
Mar 12, 2026
Current analyst consensus: Buy (79% buy). Based on 14 analysts: 5 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$7.87 mean target
+373.9% upside
Strong Buy (1.29)
$2.95 Low
$13.73 High
| Metric | Value |
|---|---|
| Current Price | $1.66 |
| Target Low | $2.95 |
| Target Mean | $7.87 |
| Target Median | $8.83 |
| Target High | $13.73 |
| # Analysts | 7 |
| Recommendation | Strong Buy (1.29) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.06 | $-0.07 | $-0.04 | 73.8% | +55.1% | 3↑ 0↓ | $0.0B | -91.1% | 4 |
| Next Q 2026-09-30 |
$-0.05 | $-0.07 | $-0.04 | 70.8% | +56.3% | 3↑ 0↓ | $0.0B | -85.3% | 4 |
| Current FY 2026-12-31 |
$-0.30 | $-0.56 | $-0.18 | 55.9% | +53.6% | 3↑ 0↓ | $0.0B | -64.8% | 5 |
| Next FY 2027-12-31 |
$-0.37 | $-0.78 | $-0.13 | -24.7% | +41.9% | 4↑ 0↓ | $0.0B | 30.7% | 5 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.055 | |
| 7d ago | $-0.122 | +0.068 |
| 30d ago | $-0.122 | +0.068 |
| 60d ago | $-0.120 | +0.065 |
| 90d ago | $-0.120 | +0.065 |
4 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Raymond James | UPGRADE | Outperform | Strong Buy |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| May 11, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Apr 21, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Mar 20, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Dec 30, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 5 | 6 | 3 | 0 | 0 | 79% | |
| May 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Apr 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Mar 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Feb 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% | |
| Jan 1, 2026 | 4 | 7 | 3 | 0 | 0 | 79% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
Recent Reddit Threads
29 APRIL 2026, WHAT ARE THE BIGGEST WINNERS TODAY
▲ 1
💬 1
⚡ 0.5
Jun 5, 2026
short_volume
Short Volume: IFRX — 55.7% short (0.3M / 0.5M)
Short: 293,591 | Exempt: 18,221 | TRF Vol: 526,740 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
May 26, 2026
short_volume
Short Volume: IFRX — 77.0% short (0.5M / 0.6M)
Short: 482,307 | Exempt: 0 | TRF Vol: 626,102 | Short Ratio: 77.0% | Off-exchange volume (dark pool + OTC)
May 22, 2026
short_volume
Short Volume: IFRX — 66.1% short (0.4M / 0.6M)
Short: 373,898 | Exempt: 0 | TRF Vol: 565,903 | Short Ratio: 66.1% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: IFRX — 72.0% short (0.6M / 0.8M)
Short: 591,745 | Exempt: 200 | TRF Vol: 821,733 | Short Ratio: 72.0% | Off-exchange volume (dark pool + OTC)
May 14, 2026
short_volume
Short Volume: IFRX — 82.2% short (1.4M / 1.7M)
Short: 1,404,390 | Exempt: 2,143 | TRF Vol: 1,708,474 | Short Ratio: 82.2% | Off-exchange volume (dark pool + OTC)
May 13, 2026
short_volume
Short Volume: IFRX — 63.8% short (1.2M / 1.9M)
Short: 1,202,491 | Exempt: 0 | TRF Vol: 1,885,285 | Short Ratio: 63.8% | Off-exchange volume (dark pool + OTC)
May 12, 2026
short_volume
Short Volume: IFRX — 58.4% short (0.8M / 1.4M)
Short: 797,704 | Exempt: 772 | TRF Vol: 1,365,654 | Short Ratio: 58.4% | Off-exchange volume (dark pool + OTC)
May 8, 2026
other
InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares
<p align="justify"><b>Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- </b> InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company
May 6, 2026
announcement
InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases
<p align="justify"><strong>Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- </strong> InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pionee
May 5, 2026
earnings_calendar
IFRX Q1 2026 Earnings Scheduled — 2026-05-05
May 5, 2026
short_volume
Short Volume: IFRX — 59.8% short (0.4M / 0.6M)
Short: 368,883 | Exempt: 26,859 | TRF Vol: 617,289 | Short Ratio: 59.8% | Off-exchange volume (dark pool + OTC)
May 4, 2026
fda
InflaRx Reports Favorable Reactive Metabolite Profile for Izicopan in Human Liver Microsomes
<p align="justify">JENA, Germany, May 04, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflamma
May 1, 2026
earnings
InflaRx to Report First Quarter 2026 Results on May 7, 2026
<p align="justify">JENA, Germany, May 01, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflamma
Apr 20, 2026
short_interest
FTD: IFRX — 345,749 shares ($0.5M) failed to deliver
Settlement: 20260420, Price: $1.59, FTD Value: $549,740.91, INFLARX N V COM (NLD)
Apr 9, 2026
fda
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
<p align="justify">JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflam